GLP-1 / weight-management follow-up
Keep GLP-1 patients on the dose, between every visit.
GLP-1 weight management lives or dies between appointments — the side effects, the dose step-ups, the patients who quietly stop. SeuSive runs clinician-supervised check-ins on the channels patients already use, so your team catches the GI complaints early, supports adherence through titration, and brings people back before they fall off. A clinician approves every message; there's nothing for the patient to download.
Why GLP-1 follow-up is hard.
The medication is only half the program. The other half happens in the weeks between visits — and that's where clinics lose patients.
The dose ladder is a string of decision points you can't see
Semaglutide steps up 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, at least four weeks per step, roughly sixteen weeks to the standard maintenance dose; tirzepatide climbs from 2.5 mg in 2.5 mg increments to a 15 mg max. Every step-up is really a tolerability decision — and it happens in the weeks you don't have eyes on the patient.
The side effects are mostly small, frequent, and manageable — but only if someone's listening
Nausea hits around 43.9% of patients on semaglutide 2.4 mg, alongside vomiting, diarrhea, constipation and abdominal pain. The reassuring part: roughly 98–99% of these GI events are non-serious and mild-to-moderate, clustering during escalation. Most resolve with smaller low-fat meals, fluids, fiber, and slower titration — not stopping. They just need a channel to surface on, and a clinician to triage the real red flags.
Roughly half of patients are gone within the first year — often before the drug has had a chance to work
Discontinuation in year one runs high — roughly half, and up to about 46–65% depending on the dataset, diabetes status, and coverage — and many quit before ever reaching a therapeutic maintenance dose, with cost and side effects among the top drivers. And stopping reverses results: in the STEP 1 extension, semaglutide patients regained about two-thirds of lost weight. Continuity is the treatment.
How SeuSive runs the GLP-1 loop.
Intake that maps the patient to their ladder
At the start, capture the drug, the current dose, and where the patient sits on their titration schedule. SeuSive then plans check-ins around the natural cadence of GLP-1 care — tighter during the every-four-week step-ups, easing out as the patient stabilizes. It's a common clinic pattern, not a rigid rule, and your clinician sets it.
Companion check-ins that catch the GI complaints — and the red flags
Between visits, the AI companion asks about weight trend, nausea, hydration, and tolerability on SMS, WhatsApp, or web. Routine GI issues get the first-line guidance your clinic approves. The serious signals — severe abdominal pain, can't keep fluids down past 24 hours, jaundice, bloody stool, fever — get flagged for urgent clinician review, never auto-answered.
Clinician review, then the rebooking or dose call
Everything lands in one staff queue. A clinician reviews and approves outreach, decides on a dose pause, reduction, or step-up, and gets the patient re-booked before they drift. No autonomous prescribing, no patient lost to silence — just your follow-up loop, running under your clinic's name.
A weigh-in isn't follow-up. The work is in the weeks nobody sees.
GLP-1 weight management is a chronic-disease therapy — it needs continued treatment plus real support: nutrition, resistance training, and monitoring that goes beyond the scale to GI tolerability, hydration, and lean-mass preservation as an emerging priority. SeuSive is the supervised layer that does that monitoring between visits, surfaces what your clinician needs to act on, and keeps the patient on the dose long enough for it to work. Your branding, your licence, your team in the loop.
Common questions.
Does SeuSive prescribe GLP-1 medications or adjust doses on its own?
No. SeuSive never diagnoses, prescribes, or changes a dose autonomously. The AI companion runs follow-up check-ins and drafts outreach, but every message and every clinical decision — a dose pause, reduction, or step-up — is reviewed and approved by a clinician in your team. It's a supervised follow-up tool, not an autonomous prescriber.
How does it handle GLP-1 side effects between visits?
The companion checks in on nausea, vomiting, diarrhea, constipation, hydration, and weight trend on the patient's usual channel. Most GI complaints are mild-to-moderate and respond to first-line measures your clinic configures — smaller low-fat meals, fluids, fiber, slower titration. Genuine red flags, like severe abdominal pain, inability to keep fluids down beyond 24 hours, jaundice, bloody stool, or fever, are flagged for urgent clinician evaluation rather than answered automatically.
Can it help with first-year discontinuation and adherence?
That's the core use case. Discontinuation in the first year is high — roughly half of patients, and higher in some datasets — and people often stop before reaching a therapeutic maintenance dose. By keeping a steady, clinician-supervised touchpoint through the titration weeks and beyond, SeuSive helps catch the side-effect and motivation problems that drive drop-off early, and brings quiet patients back into the schedule before they're gone for good.
Do patients need to download an app?
No. Patients are reached on channels they already use — SMS, WhatsApp, or web. There's nothing to install, no login to forget, and no new habit to build. For a population where convenience is part of why people stay on therapy, removing the app barrier matters.
Is the follow-up branded as SeuSive or as our clinic?
Your clinic. SeuSive is fully white-label — the whole loop, from intake through check-ins to rebooking, carries your clinic's name and voice. Patients experience it as their clinic following up with them, because that's exactly what it is.
What does the monitoring track beyond weight?
Weight trend is the start, not the whole picture. Between visits SeuSive tracks GI tolerability and hydration, and supports the broader chronic-care story — nutrition and resistance training — with body composition and lean-mass preservation as an emerging monitoring priority. A meaningful share of weight lost can be lean mass, so preserving muscle is increasingly part of good GLP-1 follow-up, not just a number on the scale.
Is it safe and compliant with patient data rules?
SeuSive is HIPAA-aware and GDPR-ready, and no production patient data is processed until tenancy, hosting, retention, and access controls are configured and approved for your clinic. The model is administrative and supervisory by design: it supports your workflow under clinician oversight, and does not provide autonomous diagnosis, prescribing, or emergency services.
Want it on paper?
Get the GLP-1 follow-up playbook.
The check-in cadence through titration, the red-flag triage rules, and the clinician safety model — in one page. No spam.
See the GLP-1 follow-up loop.
Twenty minutes. We'll show how supervised check-ins run through titration, how red flags escalate to your clinician, and how patients get rebooked — then you decide.